Article summary
This double-blind randomised midazolam-controlled clinical trial (n=68) found that four intravenous ketamine infusions (35β53 mg/70 kg) over two weeks reduced depressive symptoms more than midazolam in adults with treatment-resistant bipolar I or II depression. No mania, hypomania, psychosis, or suicide attempts occurred, although one participant in each group developed subthreshold mixed features.
Continue to the original publication for the complete article.